Effectiveness Study on Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3
NCT ID: NCT00565396
Last Updated: 2007-11-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
400 participants
INTERVENTIONAL
2004-09-30
2008-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Fosinopril 10mg/day(oral)
Fosinopril and Losartan
Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)
2
Fosinopril 20mg/day(oral)
Fosinopril and Losartan
Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)
3
Losartan 50mg/day(oral)
Fosinopril and Losartan
Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)
4
Losartan 100mg/day(oral)
Fosinopril and Losartan
Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fosinopril and Losartan
Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Roll out secondary renal diseases
* Do not use steroids and immunosuppresive drugs
* ACEI/ARB treated patients should have 7-14 days wash out period，SiDBP\< 110mmHg
* Willing and able to comprehend and give written informed consent
* Willing to follow-up regularly
Exclusion Criteria
* Secondary renal diseases
* Acute cardio-cerebral diseases within 6 months
* Post renal transplantation
* Pregnant/Nursing women
* History of hypersensitivity to ACEI/ARB
* Refuse to join clinical trial
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Municipal Health Bureau
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nan Chen, M.D.
Role: STUDY_CHAIR
Ruijin Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Taizhou People's Hospital
Taizhou, Jiangsu, China
The 1st Affiliated Hospital of College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Guangxing Hospital
Hangzhou, Zhejiang, China
Shaoyifu Hospital
Hangzhou, Zhejiang, China
Ningbo Lihuili Hospital
Ningbo, Zhejiang, China
Wenling 1st People's Hospital
Wenling, Zhejiang, China
The First affiliated Hospital of Wenzhou Medical College
Wenzhou, Zhejiang, China
Xiangshan People's Hospital
Xiangshan, Zhejiang, China
Renji Hospital
Shanghai, , China
Changzheng Hospital
Shanghai, , China
Shanghai 9th People's Hospital
Shanghai, , China
Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine
Shanghai, , China
Zhongshan Hospital
Shanghai, , China
Huadong Hospital
Shanghai, , China
Huashan
Shanghai, , China
Shanghai 455 Hospital
Shanghai, , China
Shanghai 85 Hospital
Shanghai, , China
Tongji Hospital
Shanghai, , China
Shanghai 10th People's Hospital
Shanghai, , China
Shanghai 1st People's Hospital
Shanghai, , China
Shanghai Yangpu District Centre Hospital
Shanghai, , China
Xinhua Hospital
Shanghai, , China
Shanghai East Hospital
Shanghai, , China
Shanghai 6th people's hospital
Shanghai, , China
Shanghai Changning District Centre Hospital
Shanghai, , China
Changhai Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2003ZD002
Identifier Type: -
Identifier Source: secondary_id
2003ZD002
Identifier Type: -
Identifier Source: org_study_id